Epilepsy Alliance America is pleased to announce we have joined as a member of the Alliance for Comprehensive Testing (ACT), or ACT Against COVID. As a member of the alliance, we’re dedicated to educating the epilepsy community about the importance of and information on comprehensive COVID-19 testing. With the use of COVID-19 testing strategies, we can help protect our community and get […]

Read Full Post

The safety and well-being of those in the epilepsy community who were impacted by the widespread devastation caused by Hurricane Ida in both the Gulf region and in the Northeast are a top priority to Epilepsy Alliance America Though the storm hit over 10 days ago, many people remain displaced or without electricity, and finding […]

Read Full Post

Epilepsy Alliance America is proud to have joined the International Bureau for Epilepsy (IBE) as an Associate Chapter member.  EAA’s participation was ratified at the IBE’s General Assembly meeting on Friday, September 3, 2021. Epilepsy Alliance America is proud be part of the global epilepsy movement and a new member IBE. IBE is an international […]

Read Full Post

A special promo offer is now available for the EAA Network — a 30% discount off of regular priced Student/Family Caregiver tickets. The discount is available only through this special link. This year’s conference offers an exciting speaker line up, including keynotes, Ted Talk speakers, pre-conference film screening, and more! Read more about the conference.       […]

Read Full Post

Epidiolex®, a cannabidiol (CBD) oral solution by Greenwich Biosciences, is now indicated for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS) or Tuberous Sclerosis Complex in patients one year of age or older. Read more about this development in Drug Topics. Learn More      

Read Full Post

In January 2020 the World Health Organization (WHO) declared the outbreak in China of a new coronavirus disease, COVID-19, to be a Public Health Emergency of International Concern. WHO stated that there was a high risk of COVID-19 spreading to other countries around the world. In March 2020, WHO made the assessment that COVID-19 could […]

Read Full Post

The emerging circumstances surrounding the spread of coronavirus disease 2019 (COVID-19) are evolving rapidly. Please stay informed by visiting the CDC’s COVID-19 page regularly. We care deeply about the well-being of our community, and we urge everyone to follow best practices as outlined by their local officials to stay safe and healthy during this time.

Read Full Post

Ella the Jellyfish Brings Comfort and Support to Children with LGS as well as their Families and Caregivers WOODCLIFF LAKE, NJ, November 12, 2019 /PRNewswire/ — Eisai Inc., the U.S. subsidiary of Eisai Co., Ltd., today announced the launch of Ella the Jellyfish, the first Amazon Alexa skill designed for those affected by Lennox-Gastaut Syndrome […]

Read Full Post

Pangyo, Gyeonggi Province, Korea and Paramus, New Jersey, USA, November 21, 2019 – SK Biopharmaceuticals, Co., Ltd., an innovative global pharmaceutical company focused on developing and bringing treatments to market for central nervous system (CNS) disorders, and its U.S. subsidiary SK Life Science, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved […]

Read Full Post

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, honors National Epilepsy Awareness Month in the United States this November. The company is working to bring more awareness to epilepsy, the fourth most common neurological disorder impacting more than 65 million people of all ages around the world. Read The Full Story

Read Full Post